JAMES HEALY
CIK 1245624 · last filed 2026-06-12
JAMES HEALY is a corporate insider who has filed 151 SEC Form 4 insider transactions across 21 companies since 2007. The most recent filing, for BIOA, was dated Jun 12, 2026. Across all open-market trades the lifetime net is +$113.8M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $557.2M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$557.20M
21
151
$113.76M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| BIOA | Director | 2,227,124 | $21.92 | $48.82M | $12.00M | 3 | 2026-06-12 |
| RAPP | Director | 39,661 | $41.96 | $1.66M | $10.58M | 4 | 2026-06-10 |
| SPTX | Director | 2,731,538 | $19.90 | $54.36M | $0 | 1 | 2026-05-04 |
| Y-mAbs Therapeutics, Inc. (YMAB) Delisted | Director | 2,250,961 | $8.61 | $19.38M | $10.52M | 10 | 2025-07-02 |
| NTRA | Director | 1,596,540 | $252.22 | $402.68M | -$22.23M | 33 | 2025-04-29 |
| BOLT | Director | 115,222 | $4.02 | $463.2K | $9.00M | 5 | 2024-06-14 |
| Karuna Therapeutics, Inc. (KRTX) Delisted | Director | 0 | $329.83 | $0 | $44.62M | 16 | 2024-03-18 |
| AVBP | Director | 1,252,308 | $29.98 | $37.54M | $8.00M | 1 | 2024-01-31 |
| CinCor Pharma, Inc. (CINC) Delisted | Director | 6,103,360 | $29.06 | $177.36M | $20.38M | 3 | 2022-08-15 |
| CHRS | Director | 70,086 | $1.44 | $100.9K | -$22.15M | 19 | 2022-02-11 |
| Iterum Therapeutics plc (ITRM) Delisted | Director | 115,511 | $0.03 | $3.5K | $6.50M | 5 | 2020-01-23 |
| Entasis Therapeutics Holdings Inc. (ETTX) Delisted | 10%+ Owner | 842,454 | $2.19 | $1.84M | $25.33M | 1 | 2018-10-02 |
| EDGE | Director | 142,636 | $49.76 | $7.10M | $8.90M | 4 | 2017-06-21 |
| AMRN | Director | 320,579 | $13.95 | $4.47M | -$47.71M | 13 | 2016-07-13 |
| HYPERION THERAPEUTICS INC (HPTX) Delisted | Director | 0 | — | — | -$3.55M | 3 | 2015-05-08 |
| ALIMERA SCIENCES INC (ALIM) Delisted | 10%+ Owner | 169,753 | $5.54 | $940.4K | $0 | 1 | 2014-09-15 |
| MARINUS PHARMACEUTICALS, INC. (MRNS) Delisted | 10%+ Owner | 7,000 | $0.55 | $3.9K | $54.05M | 1 | 2014-08-07 |
| Anthera Pharmaceuticals Inc (ANTH) Delisted | Director | 10,719 | — | — | -$474.0K | 8 | 2013-05-20 |
| HUMANIGEN, INC (KBIO) Delisted | Director | 3,173 | — | — | $0 | 2 | 2013-05-02 |
| Paratek Pharmaceuticals, Inc. (NOVC) Delisted | Director | 2,178,437 | — | — | $0 | 3 | 2008-03-31 |
| COTHERIX INC (CTRX) Delisted | Director | 0 | — | — | $0 | 2 | 2007-01-10 |
Recent Filings
151 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-12 | BIOA | Grant (A) | — | $0 | EDGAR |
| 2026-06-10 | RAPP | Grant (A) | — | $0 | EDGAR |
| 2026-05-04 | SPTX | Conv (C) | +2,731,538 | $0 | EDGAR |
| 2025-09-18 | — | Mixed | −2,250,961 | -$19.14M | |
| 2025-07-02 | Y-mAbs Therapeutics, Inc. (YMAB) Delisted | Grant (A) | +25,080 | $0 | EDGAR |
| 2025-06-18 | RAPP | Grant (A) | — | $0 | EDGAR |
| 2025-06-09 | BIOA | Grant (A) | — | $0 | EDGAR |
| 2025-04-29 | NTRA | Grant (A) | +142 | $0 | EDGAR |
| 2025-02-04 | NTRA | Grant (A) | +114 | $0 | EDGAR |
| 2024-10-29 | NTRA | Grant (A) | +153 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.